Moderate Aortic Stenosis: We Should Start Assessing It More Thoroughly

Moderate aortic stenosis (MAS) encompasses a broader spectrum than severe aortic stenosis. However, its progression has not yet been fully elucidated. While there are reports suggesting that this condition is not as benign as initially believed, there is a need to consider early interventions in certain instances.

Estenosis aórtica moderada: debemos comenzar a evaluarla mejor

Researchers conducted an analysis from January 2016 to June 2020 involving 674 patients with MAS. This category was defined as an aortic valve area between 1 cm² and 1.5 cm², a mean gradient between 20 mmHg and 40 mmHg, and a peak velocity of less than 4 m/s.

Patient average age was 75 years and 57% of subjects were male. Among the total, 81% had hypertension, 38% had diabetes, 49% had coronary artery disease, 28% had had a stroke, 44% had atrial fibrillation, 75% had elevated NT-pro BNP levels, and 70% had an eGFR <60. Ejection fraction was 60%; the mean gradient, 33 mmHg; peak velocity, 3.42 m/s; and aortic valve area, 1.2 cm². There was severe calcification in 13% of cases and moderate calcification in 72% of them, and 10% had bicuspid valve.

During one year of follow-up, there were major adverse cardiovascular events (MACE) in 45.3% of cases, while mortality reached 19.6%. A total of 114 patients (16.9%) required aortic valve replacement, of which 45 underwent transcatheter aortic valve implantation (TAVI) and 21.4% were hospitalized due to heart failure.

Read also: bRight: Impact and Safety of the TriClip Device in a Real-World Cohort.

Predictors of MACE included elevated levels of NT-pro BNP, presence of diabetes, elevated mitral E-wave, and the existence of atrial fibrillation at the time of diagnosis.

Conclusion

These findings shed light on the relatively unfavorable short-term prognosis and patient stratification in moderate aortic stenosis. Furthermore, they support the need for randomized studies to evaluate the effectiveness of percutaneous treatments, such as aortic valve replacement, in this specific population.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Predictors of Major Adverse Cardiovascular Events in Patients With Moderate Aortic Stenosis: Implications for Aortic Valve Replacement.

Reference: Travis Howard, et al. Circ Cardiovasc Imaging. 2023;16:e015475. DOI: 10.1161/CIRCIMAGING.123.015475.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...